(Q36190145)

English

Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1 reference

based on heuristic

inferred from title

author name string

Raphael Hagmann

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Viviane Hess

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Alfred Zippelius

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sacha I Rothschild

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

publication date

15 September 2015

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1148-1154

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4615351

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4615351

1 October 2017

The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4615351

1 October 2017

Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4615351

1 October 2017

Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4615351

1 October 2017

A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4615351

1 October 2017

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4615351

1 October 2017

Small cell lung cancer: state of the art and future perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4615351

1 October 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4615351

1 October 2017

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4615351

1 October 2017

Evidence-based medicine. A new approach to teaching the practice of medicine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4615351

1 October 2017

The periodic health examination. Canadian Task Force on the Periodic Health Examination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4615351

1 October 2017

The international system for staging lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4615351

2 July 2018

Small steps of improvement in small-cell lung cancer (SCLC) within two decades: a comprehensive analysis of 484 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4615351

22 September 2018

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4615351

21 October 2018

Treatment of small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4615351

21 October 2018

Small-cell lung cancer: treatment progress and prospects

1 reference

https://pubmed.ncbi.nlm.nih.gov/26516363

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26516363

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reinduction chemotherapy in small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26516363

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://pubmed.ncbi.nlm.nih.gov/26516363

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.7150/JCA.13080

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36190145&oldid=1531110793"